Amalia Karahalios
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amalia Karahalios has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Dallas R. English
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
27 shared publications - Brigid M. Lynch
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
23 shared publications - Roger L. Milne
Cancer Council Victoria
23 shared publications - Seyyedeh Ghazaleh Dashti
Clinical Epidemiology and Biostatistics Unit Murdoch Children's Research Institute Melbourne Victoria Australia
22 shared publications - Vivian Viallon
Nutrition and Metabolism Branch, International Agency for Research on Cancer, Lyon, France
22 shared publications - Christopher T. V. Swain
Department of Physiotherapy, Melbourne School of Health Sciences, The University of Melbourne, Melbourne, VIC, Australia
21 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by Springer Nature in BMC Medical Research Methodology
Synthesis of comparisons of multiple interventions in infectious diseases research: a scoping review
Background: Evidence synthesis in infectious diseases research often involves comparing multiple interventions to assess relative efficacy or safety, usually through pairwise or network meta-analyses. However, the statistical methods used and whether they are applied appropriately in practice are frequently unclear. This scoping review provides an overview of how comparisons of multiple interventions are synthesised in infectious diseases research. Methods: A systematic search was conducted in PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews using search terms related to meta-analyses and infectious diseases. Systematic reviews were included if they quantitatively compared three or more interventions for the prevention or treatment of infectious diseases. Results: Of the 8160 records identified, 420 systematic reviews were eligible after full text screening. A random sample of 200 systematic reviews was selected for data extraction: 100 each from 2015–2019 and 2020–2024, to ensure representation of pre- and post-COVID infectious diseases. Systematic reviews of interventions for COVID-19 (n = 32), HIV/AIDS (n = 22), and hepatitis B (n = 22) were most common. Therapeutic interventions were assessed in 153 (76.5%) systematic reviews and preventive treatments in 47 (23.5%). For statistical comparison of interventions, 34 (17.0%) systematic reviews used only pairwise meta-analyses, 88 (44.0%) used only network meta-analyses, and 78 (39.0%) used both. Of the 166 network meta-analyses, 83 (50.0%) were implemented using a Bayesian framework. Only 41 (24.7%) assessed transitivity, that is, whether it is appropriate to combine evidence from direct and indirect comparisons of interventions, and 112 (67.5%) evaluated consistency, which quantifies the agreement between the effect estimates from direct and indirect comparisons. Conclusion: Network meta-analysis is widely adopted in infectious diseases research. However, the key assumption of transitivity is rarely assessed. Improved adherence to publicly accessible protocols, thorough evaluation of assumptions, and transparent reporting is needed to improve the validity and reproducibility of evidence synthesis in infectious diseases research.
- 13 October 2026
- Published by Springer Nature in BMC Medical Research Methodology
Open AccessSynthesis of comparisons of multiple interventions in infectious diseases research: a scoping review
Background: Evidence synthesis in infectious diseases research often involves comparing multiple interventions to assess relative efficacy or safety, usually through pairwise or network meta-analyses. However, the statistical methods used and whether they are applied appropriately in practice are frequently unclear. This scoping review provides an overview of how comparisons of multiple interventions are synthesised in infectious diseases research. Methods: A systematic search was conducted in PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews using search terms related to meta-analyses and infectious diseases. Systematic reviews were included if they quantitatively compared three or more interventions for the prevention or treatment of infectious diseases. Results: Of the 8160 records identified, 420 systematic reviews were eligible after full text screening. A random sample of 200 systematic reviews was selected for data extraction: 100 each from 2015–2019 and 2020–2024, to ensure representation of pre- and post-COVID infectious diseases. Systematic reviews of interventions for COVID-19 (n = 32), HIV/AIDS (n = 22), and hepatitis B (n = 22) were most common. Therapeutic interventions were assessed in 153 (76.5%) systematic reviews and preventive treatments in 47 (23.5%). For statistical comparison of interventions, 34 (17.0%) systematic reviews used only pairwise meta-analyses, 88 (44.0%) used only network meta-analyses, and 78 (39.0%) used both. Of the 166 network meta-analyses, 83 (50.0%) were implemented using a Bayesian framework. Only 41 (24.7%) assessed transitivity, that is, whether it is appropriate to combine evidence from direct and indirect comparisons of interventions, and 112 (67.5%) evaluated consistency, which quantifies the agreement between the effect estimates from direct and indirect comparisons. Conclusion: Network meta-analysis is widely adopted in infectious diseases research. However, the key assumption of transitivity is rarely assessed. Improved adherence to publicly accessible protocols, thorough evaluation of assumptions, and transparent reporting is needed to improve the validity and reproducibility of evidence synthesis in infectious diseases research.
- Open Access
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
NMA-KIT: An interactive knowledge translation tool for network meta-analysis to bridge evidence and practice
Background and Objective: Network meta-analysis (NMA) is increasingly used to compare multiple interventions and inform clinical guidelines, health policy, and decision-making. However, inconsistent reporting and challenges in communicating complex findings can limit the accessibility, transparency, and practical application of NMA results. To address these challenges, we developed the NMA Knowledge Interactive Translation (NMA-KIT) tool, an interactive web-based application integrated within NMAstudio 2.0, to enable a seamless workflow from analysis to communication of results.Methods: The tool was developed to enable a seamless workflow from analysis to communication of results and was demonstrated using an exemplar NMA of systemic treatments for psoriasis.Results: NMA-KIT provides a structured and user-friendly framework for communicating NMA findings. The Detailed Report enables in-depth exploration of treatment effects, underlying data, assumptions, and certainty of evidence, whereas the KIT Summary presents concise, clinically focused results. Additional functionalities include interactive data filtering, customizable visualizations, absolute risk estimation, access to study-level information, and collaborative project sharing.Conclusions: NMA-KIT represents an important step forward for bridging the gap between NMA results and decision-making. By combining interactive visualization, flexible exploration, and integrated project sharing within NMAstudio 2.0, the tool improves transparency, reproducibility, and communication, ultimately supporting more informed and collaborative evidence-based decisions.
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNMA-KIT: An interactive knowledge translation tool for network meta-analysis to bridge evidence and practice
Background and Objective: Network meta-analysis (NMA) is increasingly used to compare multiple interventions and inform clinical guidelines, health policy, and decision-making. However, inconsistent reporting and challenges in communicating complex findings can limit the accessibility, transparency, and practical application of NMA results. To address these challenges, we developed the NMA Knowledge Interactive Translation (NMA-KIT) tool, an interactive web-based application integrated within NMAstudio 2.0, to enable a seamless workflow from analysis to communication of results.Methods: The tool was developed to enable a seamless workflow from analysis to communication of results and was demonstrated using an exemplar NMA of systemic treatments for psoriasis.Results: NMA-KIT provides a structured and user-friendly framework for communicating NMA findings. The Detailed Report enables in-depth exploration of treatment effects, underlying data, assumptions, and certainty of evidence, whereas the KIT Summary presents concise, clinically focused results. Additional functionalities include interactive data filtering, customizable visualizations, absolute risk estimation, access to study-level information, and collaborative project sharing.Conclusions: NMA-KIT represents an important step forward for bridging the gap between NMA results and decision-making. By combining interactive visualization, flexible exploration, and integrated project sharing within NMAstudio 2.0, the tool improves transparency, reproducibility, and communication, ultimately supporting more informed and collaborative evidence-based decisions.
- 24 June 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (4)
Mechanisms underlying the effect of adiposity on risk of post-menopausal oestrogen receptor-positive breast cancer: an interventional mediation analysis
Background: Adiposity increases the risk of post-menopausal oestrogen receptor (ER)-positive breast cancer. Inflammation, insulin, and insulin-like growth factors and sex-steroid hormones may explain this effect. We performed interventional mediation analysis to estimate the effects of hypothetical interventions targeting these pathways in females with obesity on reducing their excess risk of post-menopausal ER-positive breast cancer relative to females with normal weight. Methods: The mediation analysis included 1260 post-menopausal females (352 with ER-positive breast cancer) from a case–cohort within the Melbourne Collaborative Cohort Study. A Monte Carlo g-computation approach with non-parametric bootstrapping was used to estimate the risk differences (RDs) and 95% confidence intervals (CIs) for interventional direct and indirect effects of hypothetical interventions that shift the joint distribution of inflammation, insulin, and sex-steroid hormone biomarkers in females with obesity to the levels observed in females with normal weight. Results: The estimated RD for the total effect of obesity relative to normal weight on post-menopausal ER-positive breast cancer was 16.1 (95% CI: 3.3, 30.4) per 1000 females. The RDs for indirect effects through inflammation, insulin, and sex-steroid hormones were 16.4 (95% CI: 4.3, 27.2), −8.4 (95% CI: −23.4, 1.2), and 13.0 (95% CI: 3.3, 23.7) per 1000 females, respectively. The − RD for the direct effect not via any of these three pathways was −5.3 (95% CI: −17.4, 10.6) per 1000 females. Conclusion: Inflammation and sex-steroid hormones, but not insulin, contributed to the detrimental effect of adiposity on the risk of post-menopausal ER-positive breast cancer. Interventions targeting these pathways may reduce the risk for females with obesity.
- 24 June 2026
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 55 (4)
Mechanisms underlying the effect of adiposity on risk of post-menopausal oestrogen receptor-positive breast cancer: an interventional mediation analysis
Background: Adiposity increases the risk of post-menopausal oestrogen receptor (ER)-positive breast cancer. Inflammation, insulin, and insulin-like growth factors and sex-steroid hormones may explain this effect. We performed interventional mediation analysis to estimate the effects of hypothetical interventions targeting these pathways in females with obesity on reducing their excess risk of post-menopausal ER-positive breast cancer relative to females with normal weight. Methods: The mediation analysis included 1260 post-menopausal females (352 with ER-positive breast cancer) from a case–cohort within the Melbourne Collaborative Cohort Study. A Monte Carlo g-computation approach with non-parametric bootstrapping was used to estimate the risk differences (RDs) and 95% confidence intervals (CIs) for interventional direct and indirect effects of hypothetical interventions that shift the joint distribution of inflammation, insulin, and sex-steroid hormone biomarkers in females with obesity to the levels observed in females with normal weight. Results: The estimated RD for the total effect of obesity relative to normal weight on post-menopausal ER-positive breast cancer was 16.1 (95% CI: 3.3, 30.4) per 1000 females. The RDs for indirect effects through inflammation, insulin, and sex-steroid hormones were 16.4 (95% CI: 4.3, 27.2), −8.4 (95% CI: −23.4, 1.2), and 13.0 (95% CI: 3.3, 23.7) per 1000 females, respectively. The − RD for the direct effect not via any of these three pathways was −5.3 (95% CI: −17.4, 10.6) per 1000 females. Conclusion: Inflammation and sex-steroid hormones, but not insulin, contributed to the detrimental effect of adiposity on the risk of post-menopausal ER-positive breast cancer. Interventions targeting these pathways may reduce the risk for females with obesity.
- Open Access
- 25 April 2025
- Published by Cambridge University Press (CUP) in Research Synthesis Methods
- Vol. 16 (4) , 631-649
An investigation of the impact of using contrast- and arm-synthesis models for network meta-analysis
Network meta-analysis allows the synthesis of relative effects from several treatments. Two broad approaches are available to synthesize the data: arm-synthesis and contrast-synthesis, with several models that can be fitted within each. Limited evaluations comparing these approaches are available. We re-analyzed 118 networks of interventions with binary outcomes using three contrast-synthesis models (CSM; one fitted in a frequentist framework and two in a Bayesian framework) and two arm-synthesis models (ASM; both fitted in a Bayesian framework). We compared the estimated log odds ratios, their standard errors, ranking measures and the between-trial heterogeneity using the different models and investigated if differences in the results were modified by network characteristics. In general, we observed good agreement with respect to the odds ratios, their standard errors and the ranking metrics between the two Bayesian CSMs. However, differences were observed when comparing the frequentist CSM and the ASMs to each other and to the Bayesian CSMs. The network characteristics that we investigated, which represented the connectedness of the networks and rareness of events, were associated with the differences observed between models, but no single factor was associated with the differences across all of the metrics. In conclusion, we found that different models used to synthesize evidence in a network meta-analysis (NMA) can yield different estimates of odds ratios and standard errors that can impact the final ranking of the treatment options compared.
- 25 April 2025
- Published by Cambridge University Press (CUP) in Research Synthesis Methods
- Vol. 16 (4) , 631-649
Open AccessAn investigation of the impact of using contrast- and arm-synthesis models for network meta-analysis
Network meta-analysis allows the synthesis of relative effects from several treatments. Two broad approaches are available to synthesize the data: arm-synthesis and contrast-synthesis, with several models that can be fitted within each. Limited evaluations comparing these approaches are available. We re-analyzed 118 networks of interventions with binary outcomes using three contrast-synthesis models (CSM; one fitted in a frequentist framework and two in a Bayesian framework) and two arm-synthesis models (ASM; both fitted in a Bayesian framework). We compared the estimated log odds ratios, their standard errors, ranking measures and the between-trial heterogeneity using the different models and investigated if differences in the results were modified by network characteristics. In general, we observed good agreement with respect to the odds ratios, their standard errors and the ranking metrics between the two Bayesian CSMs. However, differences were observed when comparing the frequentist CSM and the ASMs to each other and to the Bayesian CSMs. The network characteristics that we investigated, which represented the connectedness of the networks and rareness of events, were associated with the differences observed between models, but no single factor was associated with the differences across all of the metrics. In conclusion, we found that different models used to synthesize evidence in a network meta-analysis (NMA) can yield different estimates of odds ratios and standard errors that can impact the final ranking of the treatment options compared.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Estimated residual intra-class correlation coefficients for the total proportion of variation attributable to batch
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Estimated residual intra-class correlation coefficients for the total proportion of variation attributable to batch
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Overall intra-assay and inter-assay coefficients of variation from analysis of quality control samples
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Overall intra-assay and inter-assay coefficients of variation from analysis of quality control samples
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Estimated intra-batch and inter-batch reliability intra-class correlation coefficients from analysis of quality control samples
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Estimated intra-batch and inter-batch reliability intra-class correlation coefficients from analysis of quality control samples
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Figure S2 presents scatter plots of insulin (Panel A) and c-peptide (Panel B) concentration by time since last meal.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Figure S2 presents scatter plots of insulin (Panel A) and c-peptide (Panel B) concentration by time since last meal.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Figure S4 illustrates the assumed relationships between insulin, postmenopausal ER-positive breast cancer, and other measured biomarkers.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Figure S4 illustrates the assumed relationships between insulin, postmenopausal ER-positive breast cancer, and other measured biomarkers.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Figure S5 presents a scatter plot of measured versus reference values of c-peptide.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Insulin and Insulin-like Growth Factor and Risk of Postmenopausal Estrogen Receptor–Positive Breast Cancer: A Case–Cohort Analysis
Figure S5 presents a scatter plot of measured versus reference values of c-peptide.